abstract
Since the first report of V (D) J “ allelic exclusion/inclusion”and” dual BCR “in 1961, despite continuous new discoveries, the proportion and source mechanism of dual BCR under physiological conditions have been puzzling immuologists.This study takes advantage of the single cell V (D) J sequencing technology, which can perfectly match the heavy and light chains of BCR at the level of a single B cell, and obtain the full length mRNA sequence of the CDR3 region. By analyzing the pairing of functional IGH and IGL chains in single B cell from human and mouse bone marrow and peripheral blood, it was found that dual BCR B cells exhibit stable and high levels of expression.Among them, human bone marrow and peripheral blood contain about 10% dual (or multiple) BCR B cells, and mouse peripheral blood and bone marrow memory B cells contain about 20% dual (or multiple) BCR B cells. At the same time, we innovatively found that in each research sample of humans and mice, there are three (or more) functional rearrangements (mRNA level) of a single chain in a single B cell. By analyzing the position, direction and other compositional characteristics of the V(D)J gene family, we found that at least two(or more) of them are derived from over two(or more) specific allelic inclusion rearrangements of a single chromosome.(mRNA molecular level evidence).The results of this article provides new insights, new methods and modeling references for evaluating the proportion, molecular characteristics and source mechanisms of dual BCR B cells, as well as potential significance of allelic inclusion (exclusion escape) of V(D)J rearrangement.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the National Natural Science Foundation of China (82160279) and the Guizhou Province High-level Innovative Talent Fund[No.(2018)5637].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
(1) Bone marrow of healthy volunteers (BM01), Bone--10k_BMMNC_5pv2_nextgem_intron_Multiplex_vdj_b_all_contig. (2) Peripheral blood of healthy volunteers 1(HB01), https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM5550181. (3) Peripheral blood of healthy volunteers 2(HB02), https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM5550182. (4)Peripheral blood of healthy volunteers 3(HB03), https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM5550183. (5)Peripheral blood of healthy volunteers 4(HB04), https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM5831597. (6)Peripheral blood of healthy volunteers 5(HB05),https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM5831600. (7)Peripheral blood of healthy volunteers 6(HB06),https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM5831601. (8)Peripheral blood of healthy volunteers 7(HB07), 10.1038/s41421-019-0137-3. (9)Peripheral blood of healthy volunteers 8(HB08), PBMC--vdj_v1_hs_pbmc2_b_all_contig. (10)Mouse bone marrow sample 1 (bm1), https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM4154732. (11)Mouse bone marrow sample 2 (bm2), https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM4154733. (12)Peripheral blood of the BALB/c mice (PBMC_BALB/C), PBMC--vdj_v1_mm_balbc_pbmc_b_all_contig. (13)The peripheral blood of the C57BL/6 mice (PBMC_C57BL/6), PBMC-vdj_v1_mm_c57bl6_pbmc_b_all_contig.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵# joint first author
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos